(Information sent by the signatory company)
-Bugworks Research Inc. presents a poster at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023, in Geneva, Switzerland
BANGALORE, India and SARATOGA, Calif. and ADELAIDE, Australia, Dec. 8, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, presents research results on its new best-in-class dual-acting adenosine antagonists BWC2094 and BWC2562 class, with the potential to treat a variety of difficult-to-treat cancers, at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023, in Geneva, Switzerland, on December 7.
The poster highlights two lead molecules discovered from a structure- and property-guided drug discovery platform. The molecules demonstrate potent dual A2A/A2B antagonism in a variety of pathologically relevant models that recapitulate the high adenosine-driven immunosuppression found in the tumor microenvironment (TME) in several cancers. To drive differentiation and improve clinical translation, AI/ML-driven virtual trials were used to identify potential drug combinations and guide patient selection during clinical development. BWC2094 and BWC2562 demonstrate synergistic activity in combination with approved anticancer drugs in human peripheral blood trials and a proprietary patient-derived ex vivo tumor explant platform, measured by a reduction in tumor density and an increase in apoptosis/ necrosis. Furthermore, these molecules demonstrate good oral bioavailability in rodents and dogs and were found to be well tolerated for 14 days in dose range-finding toxicology studies in preclinical species. Based on the totality of the evidence, BWC2094 is ready for IND submission.
Bugworks Research is at the forefront of developing new small molecule drugs to combat difficult-to-treat cancers and drug-resistant bacterial infections. The company is building a broad portfolio of differentiated oncology programs that target critical pathways involved in cancer progression and treatment evasion.
The ESMO Immuno-Oncology Congress is an annual event that provides a forum to present the latest scientific and clinical advances in immunotherapy to various stakeholders interested in delivering innovative cancer treatments. Attendees are invited to visit the Bugworks poster on December 7, 2023, between 12:00 and 1:00 CET.
Bugworks Research Inc. (Bugworks) is a clinical-stage biopharmaceutical company that is developing novel multi-targeted therapeutic assets in the anti-infective and oncology areas by integrating the latest innovations in computational biology, pharmacology, structural biology and medicinal chemistry.
For more information, visit www.bugworksresearch.com
View original content: https://www.prnewswire.com/news-releases/bugworks-research-inc-presenta-un-poster-en-el-congreso-de-inmuno-oncologia-2023-302010007.html